Loading data for FHTX — first visit, this takes a few seconds.
Foghorn Therapeutics Inc. (FHTX)
NasdaqGM: FHTX
· Real-Time Price · USD
6.75
+0.01 (0.15%)
At close: Aug 18, 2026, 8:00 PM
Foghorn Therapeutics Inc. (FHTX) Stock Price, Analysis & Data
0.15% (1D)
No data available
| Bid | n/a |
| Market Cap | 400.85M |
| Revenue (ttm) | 36.74M |
| Net Income (ttm) | -64.58M |
| Beta | 2.83 |
| EPS (ttm) | -0.99 |
| PE Ratio (ttm) | n/a |
| Forward PE | -6.56 |
| P/B (ttm) | -4.89 |
| P/S (ttm) | 10.91 |
| Earnings Date | Nov 5, 2026 |
| Ask | n/a |
| Volume | 153,812 |
| Avg. Volume (20D) | 264,100 |
| Open | 6.62 |
| Previous Close | 6.74 |
| Day's Range | 6.43 - 6.87 |
| 52-Week Range | 3.27 - 6.95 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, o...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 23, 2020
Employees 106
Stock Exchange NasdaqGM
Ticker Symbol FHTX
Website https://foghorntx.com
Financial Performance
In 2025, Foghorn Therapeutics's revenue was 30.91M, an increase of 36.75% compared to the previous year's 22.6M. Earnings were -74.28M, a decrease of -14.24%.
Financial StatementsEarnings Surprise
Foghorn Therapeutics has released their quarterly earnings on Aug 6, 2026:
Foghorn Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2